Visualization and Quantification of Neurokinin-1 (NK1) Receptors in the Human Brain

Overview

Journal Mol Imaging Biol

Publisher Springer

Specialties Molecular Biology
Radiology

Date 2005 Sep 13

PMID 16155744

Citations 25

Authors

Jarmo Hietala

Mikko J Nyman

Olli Eskola

Aki Laakso

Tove Gronroos

Vesa Oikonen

Jorgen Bergman

Merja Haaparanta

Sarita Forsback

Paivi Marjamaki

Pertti Lehikoinen

Michael Goldberg

Donald Burns

Terence Hamill

Wai-si Eng

Alexandre Coimbra

Richard Hargreaves

Olof Solin

Affiliations

Soon will be listed here.

Abstract

Purpose: This study was conducted to develop a new positron emission tomography (PET) method to visualize neurokinin-1 (NK(1)) receptor systems in the human brain in vivo in order to examine their neuroanatomical distribution and facilitate investigations of the role of substance P, NK(1) receptors, and NK(1) receptor antagonists in central nervous system (CNS) function and dysfunction.

Methods: PET studies were conducted in 10 healthy male volunteers using a novel selective, high-affinity NK(1) receptor antagonist labeled with fluorine-18 to very high specific radioactivity (up to 2000 GBq/micromol) [F-18]SPA-RQ. Data were collected in 3D mode for greatest sensitivity. Different modeling methods were compared and regional receptor distributions determined for comparison with in vitro autoradiographic studies using postmortem human brain slices with [F-18]SPA-RQ.

Results: The studies showed that the highest uptake of [F-18]SPA-RQ was observed in the caudate and putamen. Lower binding was found in globus pallidus and substantia nigra. [F-18]SPA-RQ uptake was also widespread throughout the neocortex and limbic cortex including amygdala and hippocampus. There was very low specific uptake of the tracer in the cerebellar cortex. The distribution pattern was confirmed using in vitro receptor autoradiography with [F-18]SPA-RQ on postmortem human brain slices. Kinetic modeling of the [F-18]SPA-RQ uptake data indicated a binding potential between 4 and 5 in the basal ganglia and between 1.5 and 2.5 in the cortical regions.

Conclusions: [F-18]SPA-RQ is a novel tool for exploration of the functions of NK(1) receptors in man. [F-18]SPA-RQ can be used to define receptor pharmacodynamics and focus dose selection of novel NK(1) receptor antagonists in clinical trials thereby ensuring adequate proof of concept testing particularly in therapeutic applications related to CNS dysfunction.

Citing Articles

Endocannabinoid signaling in stress, nausea, and vomiting.

DeVuono M, Venkatesan T, Hillard C Neurogastroenterol Motil. 2024; :e14911.

PMID: 39223918 PMC: 11872018. DOI: 10.1111/nmo.14911.

Functional evaluation of NK antagonism on cue reactivity in opiate dependence; An fMRI study.

Fonville L, Paterson L, Herlinger K, Hayes A, Hill R, Nutt D Drug Alcohol Depend. 2021; 221:108564.

PMID: 33548897 PMC: 8047866. DOI: 10.1016/j.drugalcdep.2021.108564.

[F]SPA-RQ/PET Study of NK1 receptors in the Whole Body of Guinea Pig and Rat.

Gronroos T, Forsback S, Eskola O, Bergman J, Marjamaki P, Loyttyniemi E Sci Rep. 2020; 9(1):20412.

PMID: 31892711 PMC: 6938475. DOI: 10.1038/s41598-019-56848-3.

The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy.

Majkowska-Pilip A, Halik P, Gniazdowska E Pharmaceutics. 2019; 11(9).

PMID: 31480582 PMC: 6781293. DOI: 10.3390/pharmaceutics11090443.

Association between amygdala neurokinin-1 receptor availability and anxiety-related personality traits.

Hoppe J, Frick A, Ahs F, Linnman C, Appel L, Jonasson M Transl Psychiatry. 2018; 8(1):168.

PMID: 30154470 PMC: 6113290. DOI: 10.1038/s41398-018-0163-1.

References

Maubach K, Martin K, Chicchi G, Harrison T, Wheeldon A, Swain C . Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus. Neuroscience. 2002; 109(3):609-17. DOI: 10.1016/s0306-4522(01)00467-5. View

Ljungdahl A, Hokfelt T, Nilsson G . Distribution of substance P-like immunoreactivity in the central nervous system of the rat--I. Cell bodies and nerve terminals. Neuroscience. 1978; 3(10):861-943. DOI: 10.1016/0306-4522(78)90116-1. View

Sudo Y, Suhara T, Inoue M, Ito H, Suzuki K, Saijo T . Reproducibility of [11 C]FLB 457 binding in extrastriatal regions. Nucl Med Commun. 2001; 22(11):1215-21. DOI: 10.1097/00006231-200111000-00008. View

Solin O, Eskola O, Hamill T, Bergman J, Lehikoinen P, Gronroos T . Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK1 receptor quantitation: ([18F]SPA-RQ). Mol Imaging Biol. 2004; 6(6):373-84. DOI: 10.1016/j.mibio.2004.08.001. View

Kaneko T, Shigemoto R, Nakanishi S, Mizuno N . Substance P receptor-immunoreactive neurons in the rat neostriatum are segregated into somatostatinergic and cholinergic aspiny neurons. Brain Res. 1993; 631(2):297-303. DOI: 10.1016/0006-8993(93)91548-7. View

Vincent S, Satoh K, Armstrong D, Panula P, Vale W, Fibiger H . Neuropeptides and NADPH-diaphorase activity in the ascending cholinergic reticular system of the rat. Neuroscience. 1986; 17(1):167-82. DOI: 10.1016/0306-4522(86)90234-4. View

Tattersall F, Rycroft W, Cumberbatch M, Mason G, Tye S, Williamson D . The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology. 2000; 39(4):652-63. DOI: 10.1016/s0028-3908(99)00172-0. View

Baker K, Halliday G, Hornung J, Geffen L, Cotton R, TORK I . Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus. Neuroscience. 1991; 42(3):757-75. DOI: 10.1016/0306-4522(91)90043-n. View

Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M . Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet. 1995; 346(8983):1130-1. DOI: 10.1016/s0140-6736(95)91801-9. View

10.

Kramer M, Winokur A, Kelsey J, Preskorn S, Rothschild A, Snavely D . Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology. 2003; 29(2):385-92. DOI: 10.1038/sj.npp.1300260. View

11.

EULER U, Gaddum J . An unidentified depressor substance in certain tissue extracts. J Physiol. 1931; 72(1):74-87. PMC: 1403098. DOI: 10.1113/jphysiol.1931.sp002763. View

12.

Bondy B, Baghai T, Minov C, Schule C, Schwarz M, Zwanzger P . Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry. 2003; 53(6):538-42. DOI: 10.1016/s0006-3223(02)01544-5. View

13.

Whitty C, Paul M, Bannon M . Neurokinin receptor mRNA localization in human midbrain dopamine neurons. J Comp Neurol. 1997; 382(3):394-400. View

14.

Maeno H, Kiyama H, Tohyama M . Distribution of the substance P receptor (NK-1 receptor) in the central nervous system. Brain Res Mol Brain Res. 1993; 18(1-2):43-58. DOI: 10.1016/0169-328x(93)90172-l. View

15.

Watson J, Gonsalves S, Fossa A, McLean S, Seeger T, Obach S . The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol. 1995; 115(1):84-94. PMC: 1908747. DOI: 10.1111/j.1476-5381.1995.tb16324.x. View

16.

Morcuende S, Gadd C, Peters M, Moss A, Harris E, Sheasby A . Increased neurogenesis and brain-derived neurotrophic factor in neurokinin-1 receptor gene knockout mice. Eur J Neurosci. 2003; 18(7):1828-36. DOI: 10.1046/j.1460-9568.2003.02911.x. View

17.

Hesketh P, Grunberg S, Gralla R, Warr D, Roila F, de Wit R . The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052.... J Clin Oncol. 2003; 21(22):4112-9. DOI: 10.1200/JCO.2003.01.095. View

18.

Oikonen V, Allonen T, Nagren K, Kajander J, Hietala J . Quantification of [Carbonyl-(11)C]WAY-100635 binding: considerations on the cerebellum. Nucl Med Biol. 2000; 27(5):483-6. DOI: 10.1016/s0969-8051(00)00116-5. View

19.

Slifstein M, Laruelle M . Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol. 2001; 28(5):595-608. DOI: 10.1016/s0969-8051(01)00214-1. View

20.

Kramer M, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek J . Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998; 281(5383):1640-5. DOI: 10.1126/science.281.5383.1640. View